Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children

Vaccine

Volumn 31, Issue 40, 2013, Pages 4421-4427

  Ditse, Z ^a   Adrian, P V ^a   Kuwanda, L ^a   Madhi, S A ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Antibody response; Human immunodeficiency virus; Natural immunity, Protein antigens; Streptococcus pneumoniae

Indexed keywords

BACTERIAL ANTIGEN; COMMON PROTEIN ANTIGEN; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G; LYTB PROTEIN; MEMBRANE PROTEIN; PCSB PROTEIN; PHORBOL DIBUTYRATE; PSPA PROTEIN; PSPC PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; CHILD; CHILDHOOD DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

ANTIBODY RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS; NATURAL IMMUNITY, PROTEIN ANTIGENS; STREPTOCOCCUS PNEUMONIAE;

AFRICA; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; HIV INFECTIONS; HIV-1; IMMUNOGLOBULIN G; NASOPHARYNGEAL DISEASES; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RECEPTORS, CELL SURFACE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84882822599     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.097     Document Type: Article

References (54)

1. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
2. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
3. Fireman B., Black S.B., Shinefield H.R., Lee J., Lewis E., Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22:10-16.
4. Hausdorff W.P., Siber G.R., Paradiso P.R. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001, 357:950-952.
5. Shinefield H., Black S., Ray P., Fireman B., Schwalbe J., Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002, 21:182-186.
6. Siber G.R., Klugman K.P., Mäkelä P.H. Pneumococcal vaccines: the impact of conjugate vaccines 2008, ASM Press, Washington, DC.
7. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
8. Bogaert D., Hermans P.W., Adrian P.V., Rumke H.C., de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004, 22:2209-2220.
9. Crain M.J., Waltman W.D., 2nd Turner J.S., Yother J., Talkington D.F., McDaniel L.S., et al. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun 1990, 58:3293-3299.
10. McDaniel L.S., Yother J., Vijayakumar M., McGarry L., Guild W.R., Briles D.E. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987, 165:381-394.
11. Brooks-Walter A., Briles D.E., Hollingshead S.K. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 1999, 67:6533-6542.
12. Dintilhac A., Alloing G., Granadel C., Claverys J.P. Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 1997, 25:727-739.
13. Sampson J.S., O'Connor S.P., Stinson A.R., Tharpe J.A., Russell H. Cloning and nucleotide sequence analysis of PsaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp adhesins. Infect Immun 1994, 62:319-324.
14. Paton J.C., Ferrante A. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immun 1983, 41:1212-1216.
15. Godfroid F., Hermand P., Verlant V., Denoel P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79:238-245.
16. Audouy S.A., van Selm S., van Roosmalen M.L., Post E., Kanninga R., Neef J., et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007, 25:2497-2506.
17. Giefing C., Meinke A.L., Hanner M., Henics T., Minh D.B., Gelbmann D., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008, 205:117-131.
18. Holmlund E., Quiambao B., Ollgren J., Nohynek H., Käyhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 2006, 24:57-65.
19. Lebon A., Verkaik N.J., Labout J.A.M., de Vogel C.P., Hooijkaas H., Verbrugh H.A., et al. Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study. Infect Immun 2011, 79:1680-1687.
20. Prevaes S.M., van Wamel W.J., de Vogel C.P., Veenhoven R.H., van Gils E.J., van Belkum A., et al. Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage. Infect Immun 2012, 80:2186-2193.
21. Rapola S., Jäntti V., Haikala R., Syrjänen R., Carlone G.M., Sampson J.S., et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and Acute Otitis Media. J Infect Dis 2000, 182:1146-1152.
22. Adrian P.V., Bogaert D., Oprins M., Rapola S., Lahdenkari M., Kilpi T., et al. Development of antibodies against pneumococcal proteins α-enolase, immunoglobulin A1 protease, streptococcal lipoprotein rotamase A, and putative proteinase maturation protein A in relation to pneumococcal carriage and Otitis Media. Vaccine 2004, 22:2737-2742.
23. Bogaert D., Holmlund E., Lahdenkari M., De Groot R., Kilpi T., Hermans P.W.M., et al. Development of antibodies against the putative proteinase maturation protein A in relation to pneumococcal carriage and otitis media. FEMS Immunol Med Microbiol 2006, 46:166-168.
24. Hermans P.W., Adrian P.V., Albert C., Estevao S., Hoogenboezem T., Luijendijk I.H., et al. The Streptococcal lipoprotein rotamase A is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization. J Biol Chem 2006, 281:976.
25. Weiser J.N., Bae D., Fasching C., Scamurra R.W., Ratner A.J., Janoff E.N. Antibody-enhanced pneumococcal adherence requires IgA1 protease. PNAS 2003, 100:4215-4220.
26. Virolanein A., Russel W., Crain M.J., Rapola S., Käyhty H., Briles D.E. Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J 2000, 19:134-138.
27. O'Brien K.L., Nohynek H. Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 2003, 22:133-140. World Health Organization Pneumococcal Vaccine Trials Carriage Working G.
28. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
29. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25:2451-2457.
30. Madhi S.A., Adrian P., Kuwanda L., Cutland C., Albrich W.C., Klugman K.P. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization in HIV-infected and HIV-uninfected children. J Infect Dis 2007, 196:1662-1666.
31. Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010, 202:355-361.
32. Grabarek Z., Gergely J. Zero-length crosslinking procedure with the use of active esters. Anal Biochem 1990, 185:131-135.
33. Lal G., Balmer P., Stanford E., Martin S., Warrington R., Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 2005, 296:135-147.
34. Pickering J.W., Martins T.B., Greer R.W., Schroder M.C., Astill M.E., Litwin C.M., et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 2002, 117:589-596.
35. Amdahl B.M., Rubins J.B., Daley C.L., Gilks C.F., Hopewell P.C., Sanoff E.N. Impaired natural immunity to pneumolysin during human immunodeficiency virus infection in the United States and Africa. Am J Respir Crit Care Med 1995, 152:2000-2004.
36. Etuwewe O.M., Swann N., Hollingshead S., Tolmie H., Zijlstra E.E., Faragher B., et al. Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titers in HIV infected adults. Vaccine 2009, 27:3881-3884.
37. Sullivan J.H., Mitchell T.J., Steinhoff M.C. Anti-pneumolysin antibody titers in HIV sero-positive injection drug users before and after pneumococcal bacteremia. Am J Respir Crit Care Med 2001, 163:680-684.
38. McCool T.L., Cate T.R., Tuomanen E.I., Adrian P., Mitchell T.J., Weiser J.N. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun 2003, 71:5724-5732.
39. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171-1176.
40. Ulloa-Gutierrez R., Avila-Aguero M.L. 6th international symposium on pneumococci and pneumococcal diseases. Expert Rev Vaccines 2008, 7:725-728.
41. Abdullahi O., Karani A., Tigoi C.C., Mugo D., Kungu S., Wanjiru E., et al. The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS ONE 2012, 7:e30787.
42. Gill C.J., Mwanakasale V., Fox M.P., Chilengi R., Tembo M., Nsofwa M., et al. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian Women. J Infect Dis 2008, 197:1000-1005.
43. Fernandez-Tornero C., Lopez R., Garcia E., Gimenez-Gallego G., Romero A. A novel solenoid fold in the cell wall anchoring domain of the pneumococcal virulence factor LytA. Nat Struct Biol 2001, 8:1020-1024.
44. Nunes M.C., von Gottberg A., de Gouveia L., Cohen C., Kuwanda L., Karstaedt A.S., et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the Era of an antiretroviral treatment program. PLoS ONE 2011, 6:e27929.
45. Jordano Q., Falco V., Almirante B., Planes A.M., del Valle O., Ribera E., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:1623-1628.
46. Glennie S.J., Sepako E., Mzinza D., Harawa V., Miles D.J.C., Jambo K.C., et al. Impaired CD4 T cell emory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adults. PLoS ONE 2011, 6:e25610.
47. Gill C.J., Mwanakasale V., Fox M.P., Chilengi R., Tembo M., Nsofwa M., et al. Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study. Bull World Health Organ 2008, 86:929-938.
48. Balachandran P., Brooks-Walter A., Virolanein-Jukulnen A., Hollingshead S.K., Briles D.E. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumoniae and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 2002, 70:2526-2534.
49. Nguyen C.T., Kim S.Y., Kim M.S., Lee S.E., Rhee J.H. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011, 29:5731-5739.
50. Ogunniyi A.D., Folland R.L., Briles D.E., Hollingshead S.K., Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000, 68:3028-3033.
51. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007, 75:350-357.
52. Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001, 69:5997-6003.
53. Wizemann T.M., Heinrichs J.H., Adamou J.E., Erwin A.L., Kunsch C., Choi G.H. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001, 69:1593-1598.
54. Cao J., Chen D., Xu W., Chen T., Xu S., Luo J., et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 2007, 25:4996-5005.